The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Acalabrutinib window prior to frontline therapy in aggressive B-cell lymphoma
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, reports the preliminary results, including dynamic changes in circulating tumor DNA (ctDNA) from the Phase II study (NCT04002947) of acalabrutinib window prior to frontline therapy in untreated aggressive B-cell lymphoma. Acalabrutinib before frontline therapy showed activity in various subtypes of B-cell lymphoma. Additionally, early changes in ctDNA were tightly correlated with changes on CT scans and may predict response to targeted agents as early as one week. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
